Mendus AB (publ)
Stockholm Stock Exchange IMMU.ST
Mendus AB (publ) Net Income for the year ending December 31, 2023: USD -10.03 M
-
Mendus AB (publ) Net Income for the year ending December 31, 2022 was USD -13.08 M, a 13.07% change year over year.
-
Mendus AB (publ) Net Income for the year ending December 31, 2021 was USD -15.05 M, a -34.29% change year over year.
-
Mendus AB (publ) Net Income for the year ending December 31, 2020 was USD -11.21 M, a 22.38% change year over year.
-
Mendus AB (publ) Net Income for the year ending December 31, 2019 was USD -14.44 M, a -31.16% change year over year.
| Date | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) | Net Income Margin |
|---|
| CEO | Dr. Erik Manting Ph.D. |
| IPO Date | April 22, 2013 |
| Location | Sweden |
| Headquarters | Västra Trädgårdsgatan 15 |
| Employees | 30 |
| Sector | Health Care |
| Industries | |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
Past 5 years
USD 2.74
USD 0.12
USD 0.83
USD 0.15
StockViz Staff
January 15, 2025
Any question? Send us an email